Hawaii Association of Professional Nurses
Stay Connected
Become a member

SGLT2 Inhibition as a New Heart Failure Management Option

Posted about 3 years ago by Rick Ramirez in Education

Aloha everyone,

Please see below for this FREE CE opportunity

Mahalo,

The Education Committee

Makin Education HAPN

SGLT2 Inhibition as a New Heart Failure Management Option

  • Authors: Mikhail N. Kosiborod, MD
  • CME / ABIM MOC / CE Released: 4/8/2021
  • Valid for credit through: 4/8/2022

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    You Are Eligible For

    • ANCC Contact Hour(s)

Target Audience and Goal Statement

This activity is intended for cardiologists, primary care physicians, nurses, and other clinicians who treat patients with cardiovascular disease.

The goal of this activity is to improve clinicians' awareness of the latest research and best practices in treatment of heart failure (HF) and to improve practices regarding management of patients with cardiovascular disease (CVD).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Results of clinical trials for HF

Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

  • Mikhail N. Kosiborod, MD

    Vice President for Research
    Director of Cardiometabolic Center
    Saint Luke's MAHI
    Professor of Medicine
    University of Missouri-Kansas City
    Kansas City, Missouri

    Disclosure: Mikhail N. Kosiborod, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen; Applied Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim (Diabetes); Novo Nordisk; Sanofi; Vifor Pharma
    Received grants for clinical research from: AstraZeneca; Boehringer Ingelheim
    Other: Honorarium: AstraZeneca; Boehringer Ingelheim; Novo Nordisk

Editor

  • Joy P. Marko, MS, APN-C, CCMEP

    Senior Medical Education Director, Medscape, LLC 

    Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships.

CME Reviewer

  • Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosure: Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Owns stock, stock options, or bonds from: Roche

Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

For Nurses

  • Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact CME@medscape.net

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

< GOING BACK TO THE HEART OF CARDIOLOGY 2020
From Medscape Education Cardiology
CME / ABIM MOC / CE

SGLT2 Inhibition as a New Heart Failure Management Option

Authors: Mikhail N. Kosiborod, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 4/8/2021

Valid for credit through: 4/8/2022

    Disclaimer

    The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

    Medscape Education © 2021 Medscape, LLC